Medical Equipment, Supplies & Distribution

Page 3

Insulet Corp gives FY, Q1 2015 revenue guidance below analysts' estimates

Thursday, 26 Feb 2015 04:01pm EST

Insulet Corp:Expects FY 2015 revenue to be in the range of $305 to $320 million.Expects Q1 2015 revenue to be in the range of $67 to $69 million.FY 2015 revenue of $333 million - Thomson Reuters I/B/E/S.Q1 2015 revenue of $76 million - Thomson Reuters I/B/E/S.

Lombard Medical Inc reaffirms FY 2015 revenue outlook; gives Q1 2015 revenue below analysts' estimates

Thursday, 26 Feb 2015 04:00pm EST

Lombard Medical Inc:Reaffirmed that it expects to achieve revenue for FY 2015 of between $18 mln and $20 mln.Expects Q1 2015 revenue between $3.0 mln and $3.3 mln.Q1 2015 revenue of $4.9 mln - Thomson Reuters I/B/E/S.

Meridian Bioscience receives CE Marking for Two New Molecular Amplification Tests

Thursday, 26 Feb 2015 08:30am EST

Meridian Bioscience Inc:Says it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), the sixth and seventh assays on the illumi gene ((reg)) platform.Along with these two new assays, Meridian also received the CE Mark for an innovative, simple, fast and cost effective sample preparation system, M-prep ((tm)), that is designed to facilitate the isolation of Chlamydia and Gonorrhoeae from clinical samples.

Cytori Therapeutics Inc receives FDA approval for expansion of Pivotal Scleroderma STAR trial to 20 clinical sites

Thursday, 26 Feb 2015 08:00am EST

Cytori Therapeutics Inc:Announces that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States.Says the star study is an 80 patient pivotal clinical trial approved by FDA in Jan. 2015 to study the effects of Cytori's lead drug ECCS-50 for treatment of patients with hand manifestations of Scleroderma.

Great Basin Scientific Inc announces commencement of public offering

Thursday, 26 Feb 2015 08:00am EST

Great Basin Scientific Inc:Says that it has launched follow-on offering of up to 2,724,000 units at $8.80 per Unit.Each unit consists of one share of Series E preferred stock and eight Series C warrants.Each share of Series E preferred stock will be convertible into four shares of common stock and each Series C warrant will be exercisable into one share of common stock at an exercise price of $2.55 per share.Units will automatically separate into the Series E preferred stock and Series C warrants on Aug. 25, provided that the Units will separate earlier if at any time after March 27.Upon the closing of the offering, the Units will be listed on The Nasdaq Capital Market under the ticker symbol GBSNU.Dawson James Securities, Inc. is serving as the sole book runner for the offering.

MiMedx Group Inc reaffirms FY, Q1 2015 outlook

Thursday, 26 Feb 2015 07:30am EST

MiMedx Group Inc:Reiterated its previously communicated guidance for FY 2015 and Q1 2015.Expects Q1 2015 revenue in the range of $40 - $41 mln.Expects FY 2015 revenue in the range of $175 - $190 mln.Q1 2015 revenue of $40 mln - Thomson Reuters I/B/E/S.FY 2015 revenue of $183 mln - Thomson Reuters I/B/E/S.

Symmetry Surgical Inc reaffirms FY 2015 guidance

Thursday, 26 Feb 2015 07:00am EST

Symmetry Surgical Inc:Reaffirms FY 2015 guidance.Expects FY 2015 revenue to be in the range of $77 to $84 million.Expects FY 2015 EBITDA to be in the range of $6.2 to $8.0 million.

William Demant Holding A/S gives FY 2015 EBIT guidance inline with analysts' estimates

Thursday, 26 Feb 2015 02:36am EST

William Demant Holding A/S:Expects FY 2015 EBIT in range of 1.7-2.0 billion Danish crowns.FY 2015 EBIT 1.9 billion Danish crown - Thomson Reuters I/B/E/S.

Cyberonics and Sorin to merge and create a new global medical technology company

Thursday, 26 Feb 2015 12:48am EST

Sorin SpA:Cyberonics and Sorin to merge and create new medical technologies company with combined equity of about $2.7 billion.The proposed transaction has been unanimously approved by both boards.Sorin and Cyberonics will combine under a newly formed holding company, NewCo, which the parties will name prior to closing.Each Cyberonics stockholder will receive one ordinary share of NewCo for every share of Cyberonics owned and each Sorin shareholder will receive fixed ratio of 0.0472 ordinary shares of NewCo for every Sorin share owned.After transaction Sorin shareholders will own about 46 pct of NewCo, and Cyberonics shareholders will own about 54 percent, on a fully diluted basis.NewCo will be domiciled in the UK and will apply for dual-listing on NASDAQ and London Stock Exchange (LSE) and Sorin shares will cease trading on Borsa Italiana (MTA).NewCo will operate as three business units: Cardiac Surgery, Cardiac Rhythm Management and Neuromodulation, with operating headquarters in Mirandola (Italy), Clamart (France) and Houston (U.S.) respectively.The transaction is expected to be completed by the end of the third quarter of 2015.Mittel SpA and Equinox Two SCA, which control Bios SpA and Tower 6 Bis Sarl, holding in total 25.6 percent of Sorin’s shares, have entered into a support agreement with Cyberonics under which they will vote for transaction.Mittel SpA and Equinox Two Sca are expected to hold about 11.5 pct of NewCo’s shares after closing of proposed transaction.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Zacks Investment Research Inc.
$10.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.